Introducing the Concept of Virtual Control Groups into Preclinical Toxicology Testing. Steger-Hartmann T, Kreuchwig A, Vaas L, Wichard J, Bringezu F, Amberg A, Muster W, Pognan F, Barber C. ALTEX. 2020. 37(3):343-349
Computational approaches for Drug-induced liver injury (DILI) prediction: state of the art and challenges. Béquignon O, Pawar G, van de Water B, Cronin M, van Westen G. BIOMED SCI. 2019
In Silico Toxicology Data Resources to Support Read-Across and (Q)SAR. Pawar G, Madden J, Ebbrell D, Cronin M. Front. Pharmacol. 2019. 10:561
Curation and analysis of clinical pathology parameters and histopathologic findings from eTOXsys, a large database project (eTOX) for toxicologic studies. Pinches M, Thomas R, Porter R, Camidge L, Briggs K. REGUL TOXICOL PHARM. 2019. 104396
In Silico models in drug development: where we are. Piñero J, Furlong L, Sanz F. Curr Opin Pharmacol. 2018. 42:111-121
Development of an Infrastructure for the Prediction of Biological Endpoints in Industrial Environments. Lessons Learned at the eTOX Project. Pastor M, Quintana J, Sanz F. Front. Pharmacol. 2018. 9:1147
Network, Transcriptomic and Genomic Features Differentiate Genes Relevant for Drug Response Piñero J, Gonzalez-Perez A, Guney E, Aguirre-Plans J, Sanz F, Oliva B, Furlong LI. Front. Genet. 2018 9:412.
Generating modelling data from repeat-dose toxicity reports. López-Massaguer O, Pinto-Gil K, Sanz F, Amberg A, Anger L, Stolte M, Ravagli C, Marc P, Pastor M. TOXICOL SCI 2018;162(1):287-300
Legacy data sharing to improve drug safety assessment: the eTOX project. Sanz F, Pognan F, Steger-Hartmann T, Díaz C, Cases M, Pastor M, et al. Nat Rev Drug Discov. 2017; 16, 811–812